<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171572</url>
  </required_header>
  <id_info>
    <org_study_id>1160.81</org_study_id>
    <nct_id>NCT02171572</nct_id>
  </id_info>
  <brief_title>Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate safety, tolerability and,
      pharmacokinetics of dabigatran etexilate following oral administration of single and multiple
      oral doses (110mg, 150 mg b.i.d., 7 days) in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in physical examination</measure>
    <time_frame>Day 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>Day 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Day 1, Day 4-10, day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory examinations</measure>
    <time_frame>Day 1, 2, 4, 7, 11, 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 7 days after last drug intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on Day 1)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (amount of analyte that is eliminated in area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2, (terminal half-life of the analyte in plasma)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo, (mean residence time of the analyte in the body after oral administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F, (apparent clearance of the analyte in plasma following extravascular administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant in plasma at steady state)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax, (calculated as Cmax,ss/Cmax)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC, (calculated as AUCτ,ss/AUCτ,1)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>linearity index (LI)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate low</intervention_name>
    <arm_group_label>Dabigatran etexilate low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate high</intervention_name>
    <arm_group_label>Dabigatran etexilate high</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects according to the following criteria: Based upon a complete medical
             history, including the physical examination, vital signs (BP, PR and body
             temperature), 12-lead ECG, clinical laboratory tests

               -  No finding of clinical relevance.

               -  No evidence of a clinically relevant concomitant disease.

          -  Age: ≥18 and ≤45 years.

          -  Body Mass Index (BMI): ≥18 and &lt;25 kg/m2.

          -  Signed and dated written informed consent prior to admission to the trial in
             accordance with Chinese GCP.

        Exclusion Criteria:

          -  Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders.

          -  Subject can not use an adequate form of contraception from the time of the first dose
             on Day 1 up to end-of study examination.

          -  Current diseases of the central nervous system (such as epilepsy), or psychiatric
             disorders or neurological disorders.

          -  History of clinically significant orthostatic hypotension, clinically significant
             current or past fainting spells or blackouts.

          -  Chronic or relevant acute infections.

          -  History of

               -  allergy/hypersensitivity (including drug allergy) which was deemed relevant to
                  the safety assessment as judged by the investigator (excluding asymptomatic
                  seasonal rhinitis/hay fever)

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic diseases.

               -  cerebral bleeding (e.g. after a car accident).

               -  concussions (head trauma resulting in injuring to brain) with or without loss of
                  consciousness.

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least 1 month or less
             than 10 half-lives, whichever was shorter, of the respective drug prior to
             administration or during the trial.

          -  Use of aspirin (including over-the-counter medications), antiplatelet agents like
             ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory
             drugs (NSAID), coumadin like anticoagulants, chronic use of corticosteroids, heparin
             or fibrinolytic agents within 14 days prior to administration up to end-of-study
             examination.

          -  Participation in another trial with an investigational drug within 3 months prior to
             administration up to end-of-study examination.

          -  Smoker (&gt;10 cigarettes/day or inability to refrain from smoking during the trial).

          -  Alcohol abuse (more than 60 g/day; confirmed by interview).

          -  Drug abuse (confirmed by interview).

          -  Blood donation (more than 100 mL from 3 months prior to screening and any blood
             donation from screening up to end-of-study examination).

          -  Excessive physical activities (within 7 days prior to the first drug administration up
             to end-of-study examination).

          -  Any laboratory value outside the reference range that is of clinical relevance.

          -  Known hypersensitivity to the investigational drug or its excipients.

          -  Subject who was judged ineligible by the investigator or the sub-investigator.

          -  History of any familial bleeding disorder.

          -  Thrombocytes &lt; 100×109 .

          -  Pregnant female subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

